Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2014 Nov;35(11):1324-30.

Distinct outcomes in patients with different molecular subtypes of inflammatory breast cancer

Jingyu Zhou  1 , Yi Yan, Lei Guo, Huiying Ou, Jian Hai, Chaojie Zhang, Zhaoyun Wu, Lili Tang
Affiliations

Distinct outcomes in patients with different molecular subtypes of inflammatory breast cancer

Jingyu Zhou et al. Saudi Med J. 2014 Nov.

Abstract

Objectives: To determine the outcome of patients with luminal A, luminal B, human epidermal growth factor receptor-2 (HER-2) positive, and triple negative molecular subtypes of inflammatory breast cancer (IBC) using a retrospective analysis.

Methods: This study was conducted between February 2004 and February 2010 in 3 different hospitals in China. The clinical outcomes, pathological features, and treatment strategies were analyzed in 67 cases of IBC without distant metastases. A chi-square test and one-way ANOVA were used to assess outcomes between different subtypes. Overall survival (OS) was analyzed using the Kaplan-Meier method and multivariate analysis was conducted using the Cox regression model.

Results: The 2-year OS rate was 55% for the entire cohort. Median OS time among patients with luminal A was 35 months, luminal B was 30 months, HER-2 positive was 24 months, and triple negative subtypes was 20 months, and were significantly different from each other (p=0.001). Using multivariate analysis, luminal A had 76% (p=0.037), luminal B had 54% (p=0.048), and HER-2 positive subtypes had 47% (p=0.032) decreased risk of death compared with the triple negative subtype. Furthermore, elevated Ki-67 labeling was associated with increased risk of death, while the surgical treatment significantly improved patient survival.

Conclusion: Breast cancer subtypes are associated with distinct outcomes in IBC patients. Patients that presented with triple negative IBC had poorer outcome than luminal A, luminal B, and HER-2 subtypes. These results indicate that IBC is a heterogeneous disease similar to the conventional breast cancer.

PubMed Disclaimer

Figures

Figure 1
Figure 1
The inflammatory breast cancer (IBC) overall survival curves for luminal A, luminal B, human epidermal growth factor receptor (HER)-2 positive and triple negative IBC subtypes. Patients were censored if the follow-up information was unavailable due to fatality, or loss of contact.
Figure 2
Figure 2
The inflammatory breast cancer overall survival analysis using a multivariate model. Results are stratified by Ki-67 LI (A) and (B) surgical status.
See this image and copyright information in PMC

References

    1. Levine PH, Veneroso C. The epidemiology of inflammatory breast cancer. Semin Oncol. 2008;35:11–16. - PubMed
    1. Van Laere SJ, Ueno NT, Finetti P, Vermeulen P, Lucci A, Robertson FM, et al. Uncovering the molecular secrets of inflammatory breast cancer biology: an integrated analysis of three distinct Affymetrix gene expression datasets. Clin Cancer Res. 2013;19:4685–4696. - PMC - PubMed
    1. Goldhirsch A, Wood WC, Coates AS, Gelber RD, Thurlimann B, Senn HJ, et al. Strategies for subtypes--dealing with the diversity of breast cancer: highlights of the St. Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2011. Ann Oncol. 2011;22:1736–1747. - PMC - PubMed
    1. Shanbhogue AK, Karnad AB, Prasad SR. Tumor response evaluation in oncology: current update. J Comput Assist Tomogr. 2010;34:479–484. - PubMed
    1. Brouckaert O, Laenen A, Vanderhaegen J, Wildiers H, Leunen K, Amant F, et al. Applying the 2011 St Gallen panel of prognostic markers on a large single hospital cohort of consecutively treated primary operable breast cancers. Ann Oncol. 2012;23:2578–2584. - PubMed

MeSH terms